MAPT and Alzheimer disease: Jiao et al. reported that edaravone reduced amyloid β (Aβ) deposition in the APPswe/PS1 mouse model of AD, alleviated the oxidative stress induced by Aβ, and attenuated tau hyperphosphorylation, glial activation, neuroinflammation, neuronal loss, and synaptic dysfunction; and in cultures of cortical neurons, they found that edaravone prevented neurite collapse and cell death—all of these effects of edaravone are highly beneficial [25].